+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CD110 mouse mAb (green) and negative control (red).    

  
  

CD110. also known as the thrombopoietin receptor (TPO-R) or MPL, is a cytokine receptor encoded by the *MPL* gene. It belongs to the type I hematopoietic cytokine receptor family and plays a critical role in regulating megakaryocyte development, platelet production, and hematopoietic stem cell maintenance. Thrombopoietin (TPO), its ligand, binds to CD110 to activate downstream signaling pathways like JAK-STAT, PI3K/AKT, and MAPK, promoting cell survival, proliferation, and differentiation. Dysregulation of CD110 signaling is implicated in blood disorders, including thrombocytopenia, myeloproliferative neoplasms (MPNs), and leukemia.

CD110 antibodies are essential tools for studying receptor expression, activation mechanisms, and TPO/MPL interactions. In research, they are used in flow cytometry, Western blotting, and immunohistochemistry to detect CD110 in hematopoietic tissues or cell lines. Therapeutically, CD110 is a target for treating thrombocytopenia. Drugs like romiplostim (a TPO mimetic) and eltrombopag (a non-peptide TPO-R agonist) mimic TPO to stimulate platelet production, while inhibitory antibodies or small molecules are explored for MPNs associated with hyperactive CD110 signaling, such as myelofibrosis.

Mutations in *MPL* (e.g., MPL W515L) are linked to aberrant signaling and disease progression, making CD110 antibodies valuable in diagnostic panels. Ongoing research focuses on optimizing antibody specificity and developing bispecific antibodies for targeted therapies. Overall, CD110 antibodies bridge basic research and clinical applications in hematology.